Navigation Links
The hepatitis healing power of blueberry leaves
Date:8/7/2009

A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and can eventually lead to cirrhosis and liver cancer.

Among the areas of especially high Hepatitis C incidence is the Miyazaki prefecture of southern Japan, a trend that led Hiroaki Kataoka and colleagues at the University of Miyazaki and elsewhere in Japan on a search for better treatment options. Currently, there is no vaccine for HCV, and though a combination drug regimen can clear HCV infection, this treatment is only about 60% effective on average and poses risks of severe side effects.

Kataoka and colleagues believed that since HCV is localized in the liver and can take 20 years or more to develop into disease, a dietary supplement might help slow or stop disease progression. So they screened nearly 300 different agricultural products for potential compounds that suppress HCV replication and uncovered a strong candidate in the leaves of rabbit-eye blueberry (native to the southeastern US).

They purified the compound and identified it as proanthocyandin (a polyphenol similar to the beneficial chemicals found in grapes and wine). While proanthocyandin can be harmful, Kataoka and colleagues noted its effective concentration against HCV was 100 times less than the toxic threshold, and similar chemicals are found in many edible plants, suggesting it should be safe as a dietary supplement. In the meantime, the researchers now hope to explore the detailed mechanisms of how this chemical stops HCV replication.


'/>"/>

Contact: Nick Zagorski
nzagorski@asbmb.org
301-634-7366
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1

Related biology news :

1. First human gets new antibody aimed at hepatitis C virus
2. Novel antibody prevents infection by hepatitis C virus
3. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
4. When acute hepatitis develops into chronic hepatitis
5. Discovery could lead to a new animal model for hepatitis C
6. Leeds research points to new therapy for hepatitis C treatment
7. Nano vaccine for hepatitis B shows promise for third world
8. Hepatitis C virus may need enzymes help to cause liver disease
9. BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients
10. New hope for hepatitis C sufferers
11. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology: